Sino Biopharmaceutical Limited (SBMFF)
| Market Cap | 11.46B -31.7% |
| Revenue (ttm) | 4.55B +10.3% |
| Net Income | 335.03M -33.0% |
| EPS | 0.02 -32.1% |
| Shares Out | n/a |
| PE Ratio | 34.21 |
| Forward PE | 17.64 |
| Dividend | 0.01 (1.05%) |
| Ex-Dividend Date | Jun 24, 2026 |
| Volume | 4,010 |
| Open | 0.6100 |
| Previous Close | n/a |
| Day's Range | 0.6100 - 0.6100 |
| 52-Week Range | 0.5928 - 1.2400 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules... [Read more]
Financial Performance
In 2025, Sino Biopharmaceutical's revenue was 31.83 billion, an increase of 10.28% compared to the previous year's 28.87 billion. Earnings were 2.34 billion, a decrease of -33.04%.
Financial numbers in CNY Financial StatementsNews
Sino Biopharmaceutical (SBMFF) Secures Rights for GSK Respiratory Drugs in China
Sino Biopharmaceutical (SBMFF) Secures Rights for GSK Respiratory Drugs in China
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to market two respiratory drugs from British company GSK in mainland China.
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
Hong Kong-listed Sino Biopharmaceutical said on Wednesday it has granted AstraZeneca the rights to develop a drug designed to treat chronic respiratory diseases outside China for total payments of...
GSK enters into exclusive strategic collaboration with Sino Biopharm
GSK (GSK) announced that it has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBMFF), through its subsidiary Chia Tai Tianqing Pharmaceutical Group, or CTTQ, to accele...
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
GSK on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical to accelerate the launch of its hepatitis B treatment bepirovirsen in mai...
Sino Biopharmaceutical Earnings release: H2 2025
Sino Biopharmaceutical released its H2 2025 earnings on March 26, 2026, summarizing the period's financial results.
Sino Biopharmaceutical Slides: H2 2025
Sino Biopharmaceutical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.
Sino Biopharmaceutical Annual report: H2 2025
Sino Biopharmaceutical has published its H2 2025 annual report on March 26, 2026.
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Sino Biopharmaceutical Quarterly report: H1 2025
Sino Biopharmaceutical has published its H1 2025 quarterly earnings report on August 17, 2025.
Sino Biopharmaceutical Earnings release: H1 2025
Sino Biopharmaceutical released its H1 2025 earnings on August 17, 2025, summarizing the period's financial results.
Sino Biopharmaceutical Slides: H1 2025
Sino Biopharmaceutical has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 17, 2025.
Sino Biopharmaceutical Annual report: H2 2024
Sino Biopharmaceutical has published its H2 2024 annual report on March 20, 2025.
Sino Biopharmaceutical Earnings release: H2 2024
Sino Biopharmaceutical released its H2 2024 earnings on March 20, 2025, summarizing the period's financial results.
Sino Biopharmaceutical Slides: H2 2024
Sino Biopharmaceutical has posted slides in relation to its H2 2024 quarterly earnings report, which was published on March 20, 2025.
Sino Biopharmaceutical Quarterly report: H1 2024
Sino Biopharmaceutical has published its H1 2024 quarterly earnings report on August 13, 2024.
Sino Biopharmaceutical Earnings release: H1 2024
Sino Biopharmaceutical released its H1 2024 earnings on August 13, 2024, summarizing the period's financial results.
Sino Biopharmaceutical Slides: H1 2024
Sino Biopharmaceutical has posted slides in relation to its H1 2024 quarterly earnings report, which was published on August 13, 2024.
Sino Biopharmaceutical Annual report: H2 2023
Sino Biopharmaceutical has published its H2 2023 annual report on March 28, 2024.
Sino Biopharmaceutical Earnings release: H2 2023
Sino Biopharmaceutical released its H2 2023 earnings on March 28, 2024, summarizing the period's financial results.
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln
Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the compan...
Sino Biopharmaceutical Slides: FY 2024
Sino Biopharmaceutical has posted slides in relation to its FY 2024 quarterly earnings report, which was published on January 10, 2024.
Sino Biopharmaceutical Quarterly report: H1 2023
Sino Biopharmaceutical has published its H1 2023 quarterly earnings report on August 25, 2023.
Sino Biopharmaceutical Earnings release: H1 2023
Sino Biopharmaceutical released its H1 2023 earnings on August 25, 2023, summarizing the period's financial results.